FLUOCINOLONE ACETONIDE TOPICAL SOLUTION USP, 0.01% solution

País: Estados Unidos

Língua: inglês

Origem: NLM (National Library of Medicine)

Ingredientes ativos:

FLUOCINOLONE ACETONIDE (UNII: 0CD5FD6S2M) (FLUOCINOLONE ACETONIDE - UNII:0CD5FD6S2M)

Disponível em:

Bryant Ranch Prepack

Via de administração:

TOPICAL

Tipo de prescrição:

PRESCRIPTION DRUG

Indicações terapêuticas:

Fluocinolone Acetonide Topical Solution USP, 0.01% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Resumo do produto:

Fluocinolone Acetonide Topical Solution USP, 0.01% 60 mL Bottle with applicator tip STORAGE Store at room temperature 15-25°C (59-77°F); avoid freezing and excessive heat above 40°C (104°F). Store in an upright position. Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504

Status de autorização:

Abbreviated New Drug Application

Características técnicas

FLUOCINOLONE ACETONIDE TOPICAL SOLUTION USP, 0.01%- FLUOCINOLONE
ACETONIDE TOPICAL SOLUTION USP, 0.01% SOLUTION
BRYANT RANCH PREPACK
----------
FLUOCINOLONE ACETONIDE TOPICAL SOLUTION USP, 0.01%
RX ONLY
DESCRIPTION
Fluocinolone Acetonide Topical Solution, 0.01% is intended for topical
administration. The
active component is the corticosteroid fluocinolone acetonide, which
has the chemical
name pregna-1, 4-diene-3, 20-dione, 6, 9-difluoro-11,
21-dihydroxy-16, 17-[(1-
methylethylidene) bis (oxy)]-, (6α, 11β, 16α)-. It has the
following chemical structure:
Fluocinolone Acetonide Topical Solution USP, 0.01% contains
fluocinolone acetonide 0.1
mg/mL in a water-washable base of anhydrous citric acid and propylene
glycol.
CLINICAL PHARMACOLOGY
Topical corticosteroids share anti-inflammatory, anti-pruritic and
vasoconstrictive
actions.
The mechanism of anti-inflammatory activity of the topical
corticosteroids is unclear.
Various laboratory methods, including vasoconstrictor assays, are used
to compare and
predict potencies and/or clinical efficacies of the topical
corticosteroids. There is some
evidence to suggest that a recognizable correlation exists between
vasoconstrictor
potency and therapeutic efficacy in man.
PHARMACOKINETICS
The extent of percutaneous absorption of topical corticosteroids is
determined by many
factors including the vehicle, the integrity of the epidermal barrier,
and the use of
occlusive dressings.
Topical corticosteroids can be absorbed from normal intact skin.
Inflammation and/or
other disease processes in the skin increase percutaneous absorption.
Occlusive
dressings substantially increase the percutaneous absorption of
topical corticosteroids.
Thus, occlusive dressings may be a valuable therapeutic adjunct for
treatment of
resistant dermatoses (see DOSAGE AND ADMINISTRATION).
Once absorbed through the skin, topical corticosteroids are handled
through
pharmacokinetic pathways similar to systemically administered
corticosteroids.
Corticosteroids are bound to plasma proteins in varyin